tiprankstipranks
Trending News
More News >
Fosun International (HK:0656)
:0656

Fosun International (0656) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Fosun International

(OTC:0656)

Rating:52Neutral
Price Target:
HK$5.00
▲(5.93%Upside)
The overall stock score reflects significant financial challenges and unattractive valuation, balanced by a positive technical outlook. The company's financial health needs improvement, but short-term technical trends provide some optimism.

Fosun International (0656) vs. iShares MSCI Hong Kong ETF (EWH)

Fosun International Business Overview & Revenue Model

Company DescriptionFosun International Limited operates in health, happiness, wealth, and intelligent manufacturing sectors in Mainland China, Portugal, and internationally. It operates in five segments: Health, Happiness, Insurance, Asset Management, and Intelligent Manufacturing. The Health segment engages in the research, development, manufacture, sale, and trading of pharmaceutical, biopharmaceutical, and health products; and provision of medical and health management services. The Happiness segment operates and invests in tourism and leisure, fashion consumer, and lifestyle industries. The Insurance segment operates and invests in the insurance markets. The Asset Management segment engages in the asset management and market investments activities. The Intelligent Manufacturing segment operates and invests in the intelligent manufacturing business; and produces iron and steel ore. It is also involved in the capital investment and management, property development, retail, and reinsurance business; manufacture and sale of iron and steel products; provision of banking and financial, and medical consultation services, as well as digital solutions. The company was founded in 1992 and is based in Shanghai, China. Fosun International Limited is a subsidiary of Fosun Holdings Limited.
How the Company Makes MoneyFosun International generates revenue through a diversified business model that spans multiple sectors. In healthcare, it earns income from the sale of pharmaceuticals and medical devices, as well as providing medical services through its hospital networks. The tourism and leisure sector contributes through the operation of resorts, hotels, and travel services, including its ownership stake in Club Med. In wealth management and insurance, Fosun derives earnings from investment management fees, insurance premiums, and asset management services. The company's real estate operations also contribute significantly, involving the development, sale, and leasing of properties. Key partnerships with other global enterprises enhance its revenue streams by expanding market reach and operational capabilities. Fosun's strategic investments and acquisitions are crucial in maintaining and expanding its revenue base across these sectors.

Fosun International Financial Statement Overview

Summary
Fosun International faces significant financial challenges with mixed income performance, a highly leveraged balance sheet, and weak cash flow. The company needs to address its profitability issues and manage its debt levels to improve financial health.
Income Statement
45
Neutral
The income statement reveals a mixed performance. Gross profit margin is stable; however, there is a negative net profit margin indicating losses in the most recent period. Revenue has decreased slightly compared to the previous year, reflecting a challenging environment. EBIT and EBITDA margins have improved compared to two years ago, but recent losses are concerning.
Balance Sheet
60
Neutral
The balance sheet shows a moderate position with a high debt-to-equity ratio, indicating substantial leverage. Stockholders' equity has decreased, but the equity ratio is reasonable, suggesting some balance in financial structure. However, the declining equity and increasing debt are potential risks.
Cash Flow
35
Negative
The cash flow statement is weak with no available free cash flow and operating cash flow figures for the latest period. Previous periods show negative free cash flow growth and volatility in cash flow ratios, highlighting operational and investment challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue192.14B198.20B175.39B161.29B136.74B
Gross Profit51.60B50.80B57.38B55.65B50.59B
EBITDA329.02M30.50B477.14M4.05B5.02B
Net Income-4.35B1.38B538.72M10.08B8.00B
Balance Sheet
Total Assets796.53B808.39B823.15B806.28B767.72B
Cash, Cash Equivalents and Short-Term Investments152.32B152.65B157.80B164.77B173.54B
Total Debt241.86B233.57B228.36B257.87B250.87B
Total Liabilities598.99B599.81B623.52B603.16B574.64B
Stockholders Equity118.10B124.94B121.52B131.00B127.81B
Cash Flow
Free Cash Flow15.61B-3.35B-5.45B-9.64B2.73B
Operating Cash Flow26.88B9.82B1.76B-3.32B8.89B
Investing Cash Flow-126.97M17.59B35.58B-536.96M612.52M
Financing Cash Flow-14.27B-39.67B-38.12B-3.66B2.29B

Fosun International Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.72
Price Trends
50DMA
4.37
Positive
100DMA
4.33
Positive
200DMA
4.38
Positive
Market Momentum
MACD
0.09
Negative
RSI
62.10
Neutral
STOCH
70.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0656, the sentiment is Positive. The current price of 4.72 is above the 20-day moving average (MA) of 4.60, above the 50-day MA of 4.37, and above the 200-day MA of 4.38, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 62.10 is Neutral, neither overbought nor oversold. The STOCH value of 70.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0656.

Fosun International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
£154.64B10.4110.86%3.33%-3.40%-7.51%
58
Neutral
HK$10.50B4.22-2.96%7.40%3.76%-51.26%
52
Neutral
HK$38.45B44.05-3.59%0.42%-4.89%-404.51%
$20.69B17.1411.92%2.92%
$28.34B12.5311.23%4.44%
$34.29B14.502.88%4.38%
€96.97B5.7919.25%7.24%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0656
Fosun International
4.72
0.56
13.43%
GB:HSBA
HSBC Holdings
8.94
2.62
41.46%
GXYEF
Galaxy Entertainment Group
4.40
0.20
4.76%
HSNGF
Hang Seng Bank
14.98
3.12
26.31%
SUHJF
Sun Hung Kai Properties
10.77
2.75
34.29%
DE:NC2B
CNOOC Limited
2.18
-0.43
-16.48%

Fosun International Corporate Events

Fosun’s Henlius Proposes Share Option and RSU Schemes
Jun 27, 2025

Fosun International, through its subsidiary Henlius, has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, which are subject to shareholder approval. These schemes aim to grant options and RSUs to participants, potentially reducing Fosun’s shareholding in Henlius from 63.43% to 58.73%, constituting a discloseable transaction under the Hong Kong Listing Rules.

Fosun International Grants Share Options to Key Staff
Jun 27, 2025

Fosun International Limited has announced the grant of 49,530,000 share options to 154 directors and employees as part of its 2023 Option Scheme. This move aims to incentivize and retain key management and staff, potentially enhancing the company’s performance and competitiveness in its diverse sectors.

Fosun International Appoints New Non-Executive Director to Enhance Board Diversity
Jun 16, 2025

Fosun International Limited has appointed Mr. Luo Yuanli as a non-executive director, effective June 16, 2025. Mr. Luo, currently with Zhongrong Life Insurance, brings experience in management and compliance, and his appointment is expected to enhance the board’s diversity. This strategic move reflects Fosun’s commitment to strengthening its leadership team and potentially improving its governance and operational oversight.

Fosun International Announces Board Composition and Roles
Jun 16, 2025

Fosun International Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The announcement also details the roles and functions of each director within various board committees, highlighting the company’s governance structure.

Fosun International Announces Major Transaction in Jewelry Fashion Group
Jun 13, 2025

Fosun International’s subsidiary, Yuyuan, is facilitating a capital increase for its Jewelry Fashion Group, aiming to raise up to RMB2 billion from no more than 40 investors. This strategic move involves a series of transactions that will result in a deemed disposal of equity interest, reducing Fosun’s indirect holding in the group to 91.03%. The transaction is classified as a major one under Hong Kong’s Listing Rules, necessitating shareholder approval and adherence to reporting requirements.

Fosun International Enhances Governance with Nomination Committee Framework
Jun 12, 2025

Fosun International Limited has outlined the terms of reference for its Nomination Committee, which is tasked with reviewing the board’s structure, size, and diversity, as well as recommending changes to align with the company’s corporate strategy. This move is aimed at enhancing governance and ensuring the board’s composition supports the company’s strategic goals, potentially impacting its operational efficiency and stakeholder confidence.

Fosun International Approves Key Resolutions at Annual General Meeting
Jun 5, 2025

Fosun International Limited held its Annual General Meeting on June 5, 2025, where all proposed resolutions were passed with significant support. Key resolutions included the approval of financial statements, the declaration of a final dividend, the re-election of directors, and the authorization for share repurchase and issuance mandates. These decisions reflect the company’s strategic focus on maintaining strong governance and enhancing shareholder value.

Fosun International Updates on Equity Disposal in Guangzhou Taotall
May 28, 2025

Fosun International Limited has announced a supplemental agreement to the Sale and Purchase Agreement concerning the disposal of equity interest in Guangzhou Taotall Technology Co., Ltd. to Hangzhou Tianyuan Pet Products Co., Ltd. The supplemental agreement amends the terms of the original agreement, with the appraised value of Guangzhou Taotall set at RMB777 million. The transaction is contingent upon approvals from the shareholders and boards of both companies, as well as regulatory bodies.

Fosun International Announces Major Real Estate Transaction in Lisbon
May 5, 2025

Fosun International has announced a discloseable transaction involving its subsidiaries, Fidelidade – Property Europe, S.A., and others, entering into a Promissory Sale and Purchase Agreement with Banco de Portugal. This agreement involves the sale of future units, including basement carparks, of buildings A2 and A3 of the Entrecampos Project in Lisbon, Portugal, for a base consideration of EUR191,990,000. The transaction is significant as it exceeds 5% of applicable percentage ratios, making it a discloseable transaction under the Listing Rules, and highlights Fosun International’s strategic move in the real estate market.

Fosun High Technology Reports Decline in Q1 2025 Financial Performance
Apr 30, 2025

Fosun High Technology reported a slight decrease in total assets by 0.4% and a marginal increase in equity attributable to owners by 0.3% for the first quarter of 2025. However, the company experienced a significant decline in revenue from operations by 32.9% and a drop in profit attributable to owners by 27.3% compared to the same period last year, indicating challenges in maintaining its financial performance.

Fosun’s Yuyuan Reports Significant Q1 Financial Decline
Apr 28, 2025

Fosun International’s subsidiary, Shanghai Yuyuan Tourist Mart, reported a significant decline in its financial performance for the first quarter of 2025, with a 49% drop in revenue and a 71.24% decrease in net profit compared to the same period last year. This downturn reflects challenges in the market, potentially impacting stakeholders’ confidence and the company’s industry positioning.

Fosun International Announces Acquisition of Henlius Shares
Apr 25, 2025

Fosun International Limited has announced a discloseable transaction concerning the acquisition of unlisted shares of Henlius. This acquisition involves multiple shareholders, with Ms. Tseng Chi-Ling being the largest shareholder of HenLink, the seller. This strategic move is expected to enhance Fosun’s market positioning and potentially impact its stakeholders by expanding its investment portfolio.

Fosun International Announces 2025 AGM with Key Resolutions
Apr 25, 2025

Fosun International Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 5, 2025, in Shanghai, China. Key agenda items include the presentation of audited financial statements for 2024, the declaration of a final dividend, re-election of directors, and the reappointment of Ernst & Young as auditors. Additionally, resolutions will be considered for the authorization of share purchases and the issuance of new shares, which could impact the company’s market positioning and shareholder value.

Fosun International Expands Stake in Henlius to Strengthen Pharmaceutical Holdings
Apr 21, 2025

Fosun International, through its subsidiary Fosun Pharma Industrial, has increased its stake in Henlius by acquiring additional shares, bringing its total ownership to 63.43%. This acquisition, conducted through a series of transactions, highlights Fosun’s strategic focus on expanding its influence in the pharmaceutical sector. The transactions are classified as discloseable under Hong Kong’s Listing Rules, indicating their significance to the company’s financial and operational strategies.

Fosun International Announces Director Resignation
Apr 11, 2025

Fosun International Limited announced the resignation of Mr. Yu Qingfei from his position as a non-executive director, effective April 11, 2025, due to a reallocation of work. The company expressed gratitude for Mr. Yu’s contributions, and he confirmed no disagreements with the board, ensuring no issues for shareholders or the Hong Kong Stock Exchange.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 04, 2025